| 2026-09-22 | Shortage | FDA shortage status current: Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Regulator FDA drug shortages |
| 2026-09-22 | Shortage | FDA shortage status current: Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | Regulator FDA drug shortages |
| 2026-09-22 | Shortage | FDA shortage status current: Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | Regulator FDA drug shortages |
| 2026-09-22 | Shortage | FDA shortage status current: Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | Regulator FDA drug shortages |
| 2026-09-22 | Shortage | FDA shortage status current: Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | Regulator FDA drug shortages |
| 2026-09-18 | Shortage | FDA shortage status current: Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) | Regulator FDA drug shortages |
| 2026-09-18 | Shortage | FDA shortage status current: Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) | Regulator FDA drug shortages |
| 2026-08-27 | Shortage | FDA shortage status current: Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) | Regulator FDA drug shortages |
| 2026-08-27 | Shortage | FDA shortage status current: Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) | Regulator FDA drug shortages |
| 2026-08-18 | Trial | New trial registered: GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry | Trial register ClinicalTrials.gov |
| 2026-07-29 | Federal Register | Federal Register notice: Product-Specific Guidances; Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2026-07-27 | Label | FDA label revised: Liraglutide (ANDA218115) | Regulator FDA drug label register |
| 2026-07-14 | Trial | New trial registered: Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists | Trial register ClinicalTrials.gov |
| 2026-06-26 | Federal Register | Federal Register notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comm | Regulator Federal Register |
| 2026-06-24 | Label | FDA label revised: Liraglutide (ANDA218115) | Regulator FDA drug label register |
| 2026-06-24 | Trial | New trial registered: GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation | Trial register ClinicalTrials.gov |
| 2026-06-18 | Label | FDA label revised: liraglutide (ANDA217234) | Regulator FDA drug label register |
| 2026-06-08 | Warning letter | FDA warning letter to Momentum Health 360 dba Momentum Health: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-06-03 | Trial | New trial registered: Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Trial register ClinicalTrials.gov |
| 2026-05-27 | Recall | FDA recall, Class II: Lupin Pharmaceuticals Inc.. Presence of particulate matter: a white thread-like structure in the cartridge | Regulator FDA enforcement reports |
| 2026-05-15 | Trial | New trial registered: Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity | Trial register ClinicalTrials.gov |
| 2026-05-14 | Label | FDA label revised: Liraglutide (ANDA215503) | Regulator FDA drug label register |
| 2026-05-14 | Shortage | FDA shortage status to be discontinued: Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) | Regulator FDA drug shortages |
| 2026-05-01 | Federal Register | Federal Register notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act | Regulator Federal Register |
| 2026-04-16 | Label | FDA label revised: liraglutide (ANDA217234) | Regulator FDA drug label register |
| 2026-04-13 | Trial | New trial registered: Adiponectin in Patients With Metabolic Disorders | Trial register ClinicalTrials.gov |
| 2026-03-12 | Label | FDA label revised: LIRAGLUTIDE (ANDA217590) | Regulator FDA drug label register |
| 2026-03-05 | Warning letter | FDA warning letter to Novo Nordisk Inc.: Postmarketing Adverse Drug Experience Reporting Requirements | Regulator FDA warning letters |
| 2026-02-27 | Label | FDA label revised: Liraglutide (ANDA214568) | Regulator FDA drug label register |
| 2026-02-25 | Label | FDA label revised: Saxenda (NDA206321) | Regulator FDA drug label register |
| 2026-02-20 | Warning letter | FDA warning letter to Kare Solutions, LLC dba Zappy: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-02-20 | Warning letter | FDA warning letter to Levity Inc. dba Levity: False & Misleading Claims/Misbranded (Telehealth) | Regulator FDA warning letters |
| 2026-02-10 | Results | Results posted: A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2026-01-30 | Label | FDA label revised: Liraglutide (NDA022341) | Regulator FDA drug label register |
| 2026-01-28 | Trial | New trial registered: Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery | Trial register ClinicalTrials.gov |
| 2026-01-14 | Results | Results posted: A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America | Trial register ClinicalTrials.gov |
| 2026-01-12 | Label | FDA label revised: LIRAGLUTIDE (ANDA217590) | Regulator FDA drug label register |
| 2025-12-30 | Trial | New trial registered: Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Trial register ClinicalTrials.gov |
| 2025-12-26 | Trial | New trial registered: Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity | Trial register ClinicalTrials.gov |
| 2025-12-24 | Trial | New trial registered: RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. | Trial register ClinicalTrials.gov |
| 2025-12-18 | Trial | New trial registered: Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Trial register ClinicalTrials.gov |
| 2025-12-05 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2025-12-05 | Results | Results posted: Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Trial register ClinicalTrials.gov |
| 2025-11-24 | Trial | New trial registered: Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control | Trial register ClinicalTrials.gov |
| 2025-11-21 | Results | Results posted: Comparison of Type 2 Diabetes Pharmacotherapy Regimens | Trial register ClinicalTrials.gov |
| 2025-11-13 | Label | FDA label revised: Liraglutide (ANDA215421) | Regulator FDA drug label register |
| 2025-11-10 | Trial | New trial registered: Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using | Trial register ClinicalTrials.gov |
| 2025-10-16 | Label | FDA label revised: Liraglutide (ANDA217063) | Regulator FDA drug label register |
| 2025-10-14 | Label | FDA label revised: Xultophy 100/3.6 (BLA208583) | Regulator FDA drug label register |
| 2025-10-14 | Label | FDA label revised: Victoza (NDA022341) | Regulator FDA drug label register |
| 2025-10-10 | Label | FDA label revised: Liraglutide (ANDA215245) | Regulator FDA drug label register |
| 2025-09-24 | Trial | New trial registered: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis | Trial register ClinicalTrials.gov |
| 2025-09-16 | Trial | New trial registered: Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Out | Trial register ClinicalTrials.gov |
| 2025-09-09 | Warning letter | FDA warning letter to Eli Lilly and Company: False & Misleading Claims/Misbranded | Regulator FDA warning letters |
| 2025-09-09 | Warning letter | FDA warning letter to Novo Nordisk Inc.: False & Misleading Claims/Misbranded | Regulator FDA warning letters |
| 2025-08-06 | Trial | New trial registered: A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese | Trial register ClinicalTrials.gov |
| 2025-07-30 | Trial | New trial registered: Tirzepatide vs Liraglutide in Bone | Trial register ClinicalTrials.gov |
| 2025-07-08 | Results | Results posted: Liraglutide Effects on Epicardial Fat Inflammatory Genes | Trial register ClinicalTrials.gov |
| 2025-06-19 | Trial | New trial registered: Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) | Trial register ClinicalTrials.gov |
| 2025-06-11 | Trial | New trial registered: Metabolic Surgery for Atrial Fibrillation Elimination | Trial register ClinicalTrials.gov |
| 2025-05-16 | Trial | New trial registered: The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2025-05-15 | Results | Results posted: Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee | Trial register ClinicalTrials.gov |
| 2025-04-20 | Results | Results posted: Liraglutide in Adolescents With Type 1 Diabetes | Trial register ClinicalTrials.gov |
| 2025-04-13 | Trial | New trial registered: A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus | Trial register ClinicalTrials.gov |
| 2025-04-03 | Trial | New trial registered: Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity | Trial register ClinicalTrials.gov |
| 2025-04-01 | Trial | New trial registered: Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy | Trial register ClinicalTrials.gov |
| 2025-03-07 | Trial | New trial registered: Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone | Trial register ClinicalTrials.gov |
| 2025-03-03 | Results | Results posted: Liraglutide and Peripheral Artery Disease | Trial register ClinicalTrials.gov |
| 2025-02-20 | Trial | New trial registered: The Evira Study: Additional Support During Obesity Treatment | Trial register ClinicalTrials.gov |
| 2025-02-10 | Trial | New trial registered: Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists | Trial register ClinicalTrials.gov |
| 2025-01-30 | Label | FDA label revised: Liraglutide (NDA022341) | Regulator FDA drug label register |
| 2024-12-19 | Trial | New trial registered: Liraglutide Treatment in Obese Infertile PCOS Women | Trial register ClinicalTrials.gov |
| 2024-12-06 | Trial | New trial registered: Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity | Trial register ClinicalTrials.gov |
| 2024-12-03 | Label | FDA label revised: Liraglutide (ANDA215503) | Regulator FDA drug label register |
| 2024-12-02 | Label | FDA label revised: Liraglutide (ANDA215503) | Regulator FDA drug label register |
| 2024-12-02 | Trial | New trial registered: TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | Trial register ClinicalTrials.gov |
| 2024-11-20 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2024-11-20 | Results | Results posted: Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | Trial register ClinicalTrials.gov |
| 2024-11-12 | Results | Results posted: A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. | Trial register ClinicalTrials.gov |
| 2024-11-06 | Results | Results posted: Use of a GLP-1R Agonist to Treat Opioid Use Disorder | Trial register ClinicalTrials.gov |
| 2024-11-01 | Trial | New trial registered: Comprehensive Clinical Evaluation Study of GLP-1RA | Trial register ClinicalTrials.gov |
| 2024-09-27 | Results | Results posted: Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | Trial register ClinicalTrials.gov |
| 2024-09-03 | Trial | New trial registered: GLP_1 RA Ultrasound Study | Trial register ClinicalTrials.gov |
| 2024-08-19 | Trial | New trial registered: A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | Trial register ClinicalTrials.gov |
| 2024-08-13 | Results | Results posted: Saxenda in Obesity Services (STRIVE Study) | Trial register ClinicalTrials.gov |
| 2024-07-23 | Results | Results posted: Efficacy of Liraglutide Therapy in Patients With IPAA | Trial register ClinicalTrials.gov |
| 2024-07-22 | Results | Results posted: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial | Trial register ClinicalTrials.gov |
| 2024-07-16 | Results | Results posted: Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity. | Trial register ClinicalTrials.gov |
| 2024-07-15 | Trial | New trial registered: Effects of Liraglutide on Body Surface Gastric Mapping | Trial register ClinicalTrials.gov |
| 2024-07-15 | Trial | New trial registered: Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease | Trial register ClinicalTrials.gov |
| 2024-06-27 | Trial | New trial registered: Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Trial register ClinicalTrials.gov |
| 2024-06-17 | Trial | New trial registered: Risk Factors Affect Weight Loss Outcomes After Treatment. | Trial register ClinicalTrials.gov |
| 2024-06-10 | Trial | New trial registered: A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects | Trial register ClinicalTrials.gov |
| 2024-06-07 | Trial | New trial registered: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Trial register ClinicalTrials.gov |
| 2024-06-05 | Label | FDA label revised: Liraglutide (ANDA215503) | Regulator FDA drug label register |
| 2024-06-03 | Trial | New trial registered: Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D | Trial register ClinicalTrials.gov |
| 2024-05-31 | Trial | New trial registered: LIROH - Liraglutide for Obesity in HIV | Trial register ClinicalTrials.gov |
| 2024-05-22 | Results | Results posted: A Study of Tirzepatide in Overweight and Very Overweight Participants | Trial register ClinicalTrials.gov |
| 2024-05-17 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2024-05-10 | Trial | New trial registered: The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes | Trial register ClinicalTrials.gov |